Dr. Kelvin is a pioneer in the field of chemokine receptor regulation and currently holds the position of Division Head of the Experimental Therapeutics Department at the Toronto General Research Institute, University Health Network, Toronto.
Dr. Kelvin's laboratory has three main research focuses: molecular mechanisms underlying transplantation injury and tolerance, molecular modeling of immune responses with emphasis on transplantation injury and vaccine induction and viral challenges, and evolution of chemokine receptors.
As a co-leader of the CANVAC Genomics and Proteomics theme, he helps orchestrate the construction of custom immune cDNA arrays and the design, interpretation and analysis of gene expression profiles of vaccine altered immune responses and immune responses in virally challenged vaccinated and non-vaccinated individuals.
Also, he has founded TransNet, a network in which scientists from across Canada can contribute data from transplant patients in order to develop genetic models for transplant rejection and tolerance. This study has grown to be one of the largest in the world. Dr. Kelvin has expanded these studies with support by Genome Canada in a genomics and proteomics project aiming to construct integrated databases for analysis of immune responses.
The focus in Dr. Kelvin's laboratory has been on the role cytokines and chemokines play in transplantation-induced inflammation. While actively pursuing research into defining signature profiles of inflammatory gene expression during allograft and xenograft rejection in non-human primates and humans and identifying novel inflammatory genes and proteins, Dr. Kelvin's group has also begun mapping cytokine and chemokine pathways in SARS patients and investigating SARS-induced T cell responses in infected patients.
